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Abstract 
Background: Digoxin has been shown to be impact on a number of pathways that are of 
relevance to cancer and its use has been associated with increased risks of breast and uterus 
cancer and, more recently, a 40% increase in colorectal cancer risk. These findings raise 
questions about the safety of digoxin use in colorectal cancer patients and therefore we 
investigated whether digoxin use after colorectal cancer diagnosis increased the risk of 
colorectal cancer-specific mortality. 
Methods: A cohort of 10,357 colorectal cancer patients newly diagnosed from 1998 to 2009 
was identified from English cancer registries and linked to the UK Clinical Practice Research 
Datalink (to provide digoxin and other prescription records) and to the Office of National 
Statistics mortality data (to identify 2,724 colorectal cancer-specific deaths). Using time-
dependent Cox regression models, unadjusted and adjusted hazard ratios (HR) and 95% 
confidence intervals (CIs) were calculated for the association between post-diagnostic 
exposure to digoxin and colorectal cancer-specific mortality. 
Results: Overall, 682 (6%) colorectal cancer patients used digoxin after diagnosis.  Digoxin 
use was associated with a small increase in colorectal cancer-specific mortality before 
adjustment (HR=1.25; 95% CI 1.07-1.46), but after adjustment for confounders the 
association was attenuated (adjusted HR=1.10; 95% CI 0.91-1.34) and there was no evidence 
of a dose response.  
Conclusions: In this large population-based colorectal cancer cohort, there was little 
evidence of an increase in colorectal cancer-specific mortality with digoxin use after 
diagnosis.   
Impact: These results provide some reassurance that digoxin use is safe in colorectal cancer 
patients.  
 
Introduction  
The main effect of digoxin, a cardiac glycoside, is on the inhibition of the sodium potassium 
ATPase pump but it impacts a number of pathways relevant to cancer. For instance, studies 
have shown increases in breast and uterus cancer probably  related to estrogenic effects of 
digoxin (1). A recent large UK study reported a 40% increase in colorectal cancer risk in 
digoxin users (2), which the researchers suggest possibly reflect  direct effects of the sodium 
potassium ATPase pump on tumorigenic pathways such as the Src/mitogen-activated 
proteinkinase (M APK) (3). In addition, preclinical studies have found that digoxin may 
reduce chemotherapy efficacy (4). These findings raise questions about the safety of digoxin 
in colorectal cancer patients. As there has been little research into digoxin use and colorectal 
cancer progression, we investigated whether colorectal cancer patients using digoxin had 
increased colorectal cancer-specific mortality.  
 
Materials and Methods 
The data source and methods have been discussed in detail previously (5).  In brief, patients 
with newly diagnosed colorectal cancer from English cancer registries between 1998 and 
2009 were identified from the National Cancer Data Repository (NCDR).  Colorectal cancer-
specific deaths up to January 2012 were identified from the underlying cause of death from 
Office of National Statistics (ONS) death registration data.  The Clinical Practice Research 
Datalink (CPRD) provided digoxin use from GP prescribing records.  Potential confounders 
including stage, grade and treatment were determined from NCDR.  Smoking, BMI, 
deprivation and comorbidities were determined from GP records.   
 Statistical analysis 
Patients were followed up from one year after colorectal cancer diagnosis until death, end of 
GP registration, last date of data collection from GP, or end of ONS follow-up.  In the main 
analysis, time-dependent Cox regression models were used to calculate hazard ratios (HRs) 
and 95% confidence intervals (CIs) for colorectal cancer-specific death for digoxin users 
compared with non-users using a time varying covariate (lagged by 6 months). Adjusted 
analyses were conducted including potential confounders. Further analyses were conducted 
by number of digoxin prescriptions and number of DDDs.  Analyses were repeated for all-
cause mortality.  Analyses were conducted in STATA 13.  
 
Results 
The final cohort included 10,357 colorectal cancer patients with mean of 4.8 years of follow-
up from diagnosis (maximum=14 years) containing 2,724 colorectal cancer-specific deaths, 
and 1,263 deaths from other causes. Table 1 shows characteristics by digoxin use. Digoxin 
use was associated with increased colorectal cancer-specific mortality before adjustment 
(HR=1.25; 95% CI 1.07-1.46) but after adjustment for confounders the association was 
attenuated (adjusted HR=1.10; 95% CI 0.91-1.34) and no dose response associations were 
apparent.  After adjustment for confounders there was an increase in all-cause mortality in 
digoxin users (HR=1.53; 95% CI 1.34-1.73).  This increase was most marked for 
cardiovascular deaths (adjusted HR=2.73; 95% CI 2.11-3.52), as expected, and there was 
only a small increase in the risk of death for non-cardiovascular causes (adjusted HR=1.26; 
95% CI 1.08-1.47) (Table 2). A simplified analysis for colorectal cancer-specific mortality, 
based upon digoxin use in the year after diagnosis, also revealed little evidence of association 
(adjusted HR=0.98; 95% CI 0.79- 1.22). A further sensitivity analyses revealed little 
evidence of association between colorectal cancer-mortality and digoxin use in the year 
before diagnosis (adjusted HR=0.88; 95% CI 0.73- 1.06). 
 
Discussion 
We observed little evidence of increased colorectal cancer-specific mortality in digoxin users 
providing some reassurance that digoxin is safe in colorectal cancer patients, despite recent 
evidence that digoxin users may have increased colorectal cancer risk (2). Our findings do 
not support a French study which observed reduced overall mortality with digoxin in 75 
colorectal cancer patients (6), nor some pre-clinical studies suggesting that digoxin could 
have inhibitory effects on colorectal cancer cell growth (7). 
 
This study is the first population-based cohort to investigate digoxin use and colorectal 
cancer-specific mortality.  Other strengths include large size and long duration of follow-up 
but we cannot rule out the possibility of type 2 error (a power calculation, using Schoenfeld’s 
method, based on observed medication use and cancer-speciﬁc deaths, indicated that we had 
approximately 80% power to detect as signiﬁcant a HR of 1.25 for digoxin).  Although 
verification of cancer diagnosis and death were robust, misclassification of colorectal cancer 
cause of death is possible; however, methodological studies suggest that comparative risk 
estimates are unlikely to be greatly affected where misclassification is unlikely to be 
differential. Recall bias was eliminated by using routinely collected GP-prescribed drug. 
Confounding by indication, often a problem in pharmacoepidemiology, is unlikely to have 
influenced our main finding for colorectal cancer-specific mortality, but would explain the 
increase in all-cause mortality due largely to raised cardiovascular mortality in digoxin users 
(8). Misclassification of digoxin usage is possible because of non-compliance. As with all 
observational studies, confounding caused by unrecorded or incomplete potential 
confounders (e.g. stage) cannot be ruled out.  In conclusion, there was little evidence of an 
increase in colorectal cancer-specific mortality with digoxin use after diagnosis.  
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Table 1. Characteristics of colorectal cancer patients by digoxin use after diagnosis. 
Characteristics 
Digoxin use after diagnosis 
Digoxin use in first year after 
diagnosis 
Ever n (%) Never n (%) Ever n (%) Never n (%) 
 Year of diagnosis: 1998-2000 149 (22) 1,599 (17) 94(19) 1,654(17) 
                                 2001-2003 233 (34) 2,345 (24) 149(30) 2,429(25) 
                                 2004-2006  173 (25) 2,724 (28) 140(28) 2,757(28) 
                                 2007-2009 127 (19) 3,007 (31) 112(23) 3,022(31) 
Age at diagnosis: < 50  3 (0) 610 (6) 1(0) 612(6) 
                             50-59 20 (3) 1,463 (15) 10(2) 1,473(15) 
                             60-69 90 (13) 2,683 (28) 50(10) 2,723(28) 
                             70-79 299 (44) 3,204 (33) 216(44) 3,287(33) 
                             80-89 245 (36) 1,585 (16) 198(40) 1,632(17) 
                             ≥ 90 25 (4) 130 (1) 20(4) 135(1) 
Gender: Males 379 (56) 5,353 (55) 272 (55) 5,460 (55) 
Stage:  I 93 (18) 1,229 (16) 61(16) 1,261(16) 
           II 240 (45) 3,004 (39) 173(45) 3,071(39) 
           III 177 (33) 2, 914 (38) 134(35) 2,957(38) 
           IV 19 (4) 524 (7) 15 (4) 528 (7) 
           Missing 153 2,004 112 2,045 
Grade:  Well 33 (6) 547 (7) 22(6) 585(6) 
              Moderately 445 (78) 6,432 (78) 328(78) 6,549(79) 
              Poorly 92 (16) 1,259 (15) 62(16) 1,279(15) 
              Missing 112  1,420 83 1,449 
Treatment within 6 months of cancer diagnosis     
  Surgery 588 (86) 8,510 (88) 425(86) 8,673(88) 
  Chemotherapy 88 (13) 3,054 (32) 63(13) 3,079(31) 
  Radiotherapy 64 (9) 1,381 (14) 48(10) 1,397(14) 
Smoking status prior to cancer diagnosis     
  Non-smoker 232 (52) 3,498 (53) 169(51) 3,561(53) 
  Ex-smoker 167 (37) 2,145 (32) 128(39) 2,184(32) 
  Current smoker 48 (11) 969 (15) 33(10) 984(15) 
  Missing 235 3,063 165 3,133 
Alcohol consumption prior to diagnosis     
  Never 87 (20) 1,007 (16) 66(21) 1,028(16) 
  Ever 351 (80) 5,443 (84) 255(79) 5,539(84) 
  Missing 244 3,225 174 3,295 
BMI (kg/m2) prior to diagnosis: mean (sd)  27.0 (4.8) 26.5 (4.7) 26.9(5.1) 26.5(4.7) 
  Underweight (<18.5) 6 (1) 126 (2) 5(2) 127(2) 
  Normal (18.5 to 25)  147 (34) 2,407 (37) 114(36) 2,440(37) 
  Overweight (25-30) 185 (43) 2,654 (41) 130(41) 2,709(41) 
  Obese (>30) 93 (22) 1,258 (20) 68(21) 1,283(20) 
  Missing 251 3,230 178 3,303 
Deprivation fifth:  1st (least deprived) 149 (22) 2,498 (26) 112(23) 2,535(26) 
                                2nd 173 (25) 2,389 (25) 125(25) 2,437(25) 
                                3rd  151 (22) 1,986 (21) 105(21) 2,032(21) 
                                4th  121 (18) 1,694 (18) 85(17) 1,730(18) 
                                5th (most deprived) 86 (13) 1,091 (11) 66(13) 1,111(11) 
                                Missing 2 17 2 17 
Comorbidity prior to cancer diagnosis     
  Cerebrovascular disease 61 (9) 390 (4) 49(10) 402(4) 
  Chronic pulmonary disease 106 (16) 1,182 (12) 69(14) 1,219(12) 
  Congestive heart disease 85 (12) 183 (2) 72(15) 196(2) 
  Diabetes 102 (15) 758 (8) 83(17) 777(8) 
  Myocardial infarction 47 (7) 369 (4) 39(8) 377(4) 
  Peptic ulcer disease 39 (6) 398 (4) 27(5) 410(4) 
  Peripheral vascular disease 34 (5) 256 (3) 28(6) 262(3) 
  Renal disease 31 (5) 353 (4) 25(5) 359(4) 
Medication after diagnosis a     
 Low dose aspirin use (after diagnosis, in exposure period) 283 (42) 2,349 (24) 188 (38) 2,444 (25) 
 Statins use  206 (30) 2,570 (27) 148 (30) 2,628 (27) 
 Metformin use  75 (11) 637 (7) 53 (11) 659 (7) 
 ACEI use  279 (41) 2,241 (23) 186 (38) 2,334 (24) 
ACEI=angiotensin-converting-enzyme inhibitor 
a Medication use calculated in the first year after diagnosis for the comparison of digoxin users and non-users in the first year after diagnosis. 
Table 2. Association between digoxin usage after cancer diagnosis and colorectal cancer -specific and all-cause mortality. 
Medication usage after diagnosis Cancer-
specific/ 
all-cause 
mortality 
All 
patients 
Person 
years 
Unadjusted HR 
(95%CI) 
Adjusteda HR 
(95%CI) 
Cohort with stage and deprivation 
Unadjusted HR 
(95%CI) 
Adjusteda HR 
(95%CI) 
Fully adjustedb HR 
(95%CI) 
Colorectal  cancer-specific mortality 
Number of patients    [10,357] [10,357] [8,183] [8,183] [8,183] 
Digoxin non-user 2,560 9,675 36,934 1.00 1.00 1.00 1.00 1.00 
Digoxin user c 164 682 2,023 1.25 (1.07, 1.46) 1.18 (1.01, 1.40) 1.12 (0.92, 1.35) 1.11 (0.91, 1.36) 1.10 (0.91, 1.34) 
         
Digoxin non-user 2,560 9,675 36,934 1.00 1.00 1.00 1.00 1.00 
 1 to 11 Digoxin prescriptions d 82 239 780 1.26 (1.01, 1.57) 1.19 (0.95, 1.49) 1.14 (0.88, 1.49) 1.15 (0.88, 1.50) 1.10 (0.84, 1.45) 
  ≥ 12 Digoxin prescriptions d 82 443 1,243 1.24 (0.99, 1.55) 1.18 (0.94, 1.48) 1.09 (0.84, 1.43) 1.08 (0.82, 1.42) 1.10 (0.84, 1.44) 
         
Digoxin non-user 2,560 9,675 36,934 1.00 1.00 1.00 1.00 1.00 
 1 to 365 ddds d 113 358 1,090 1.30 (1.07, 1.56) 1.22 (1.00, 1.47) 1.14 (0.90, 1.43) 1.14 (0.90, 1.45) 1.10 (0.87, 1.40) 
  ≥ 365 ddds  d 51 324 933 1.15 (0.87, 1.52) 1.12 (0.84, 1.49) 1.09 (0.79, 1.49) 1.06 (0.76, 1.47) 1.10 (0.79, 1.52) 
All-cause mortality 
Number of patients    [10,357] [10,357] [8,183] [8,183] [8,183] 
Digoxin non-user 3,613 9,675 36,934 1.00 1.00 1.00 1.00 1.00 
Digoxin user c 374 682 2,023 1.96 (1.76, 2.18) 1.53 (1.37, 1.71) 1.92 (1.70, 2.17) 1.52 (1.34, 1.73) 1.52 (1.34, 1.73) 
         
Digoxin non-user 3,613 9,675 36,934 1.00 1.00 1.00 1.00 1.00 
 1 to 11 Digoxin prescriptions d 157 239 618 1.81 (1.54, 2.13) 1.44 (1.22, 1.69) 1.78 (1.48, 2.15) 1.46 (1.20, 1.76) 1.43 (1.18, 1.72) 
  ≥ 12 Digoxin prescriptions d 217 443 1,023 2.09 (1.82, 2.40) 1.60 (1.39, 1.85) 2.03 (1.73, 2.37) 1.58 (1.34, 1.86) 1.60 (1.36, 1.89) 
         
Digoxin non-user 3,613 9,675 36,934 1.00 1.00 1.00 1.00 1.00 
 1 to 365 ddds d 224 358 864 1.91 (1.67, 2.19) 1.49 (1.29, 1.71) 1.86 (1.59, 2.18) 1.50 (1.27, 1.76) 1.47 (1.25, 1.73) 
  ≥ 365 ddds  d 150 324 777 2.04 (1.73, 2.41) 1.60 (1.35, 1.89) 2.00 (1.67, 2.41) 1.57 (1.30, 1.89) 1.61 (1.33, 1.95) 
ddds, defined daily doses. 
a Model includes year of diagnosis, age at diagnosis, gender, surgery within 6 months, radiotherapy within 6 months, chemotherapy within 6 months, site (colon or rectum), comorbidities prior 
to diagnosis (including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, diabetes with complications, myocardial infarction, peptic ulcer disease, 
peripheral vascular disease, renal disease) and other medication use (after diagnosis, as time varying covariates, specifically low-dose aspirin, statins, metformin, and ACEIs). 
b Model includes all variables in a, additionally adjusted for stage and deprivation (in fifths) in individuals with non-missing values. 
c Digoxin use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first digoxin usage and a user after this time, excludes deaths in the year after 
cancer diagnosis. 
d Digoxin use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage, a user of 0 to 12 prescriptions (or 365th defined daily 
doses) from 6 months after first prescription to 6 months after 12th prescription (or 365th defined daily dose) and a greater user after this time, excludes deaths in the year after cancer diagnosis. 
